These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 16229924)

  • 41. Effect of antiobesity medications in patients with type 2 diabetes mellitus.
    Choussein S; Makri AA; Frangos CC; Petridou ET; Daskalopoulou SS
    Diabetes Obes Metab; 2009 Jul; 11(7):641-64. PubMed ID: 19236442
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The discovery and status of sibutramine as an anti-obesity drug.
    Luque CA; Rey JA
    Eur J Pharmacol; 2002 Apr; 440(2-3):119-28. PubMed ID: 12007530
    [TBL] [Abstract][Full Text] [Related]  

  • 43. What role for weight-loss medication? Weighing the pros and cons for obese patients.
    Wyatt HR; Hill JO
    Postgrad Med; 2004 Jan; 115(1):38-40, 43-5, 58. PubMed ID: 14755876
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Current pharmacological approaches to the treatment of obesity.
    Hauner H
    Int J Obes Relat Metab Disord; 2001 May; 25 Suppl 1():S102-6. PubMed ID: 11466601
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Currently available drugs for the treatment of obesity: Sibutramine and orlistat.
    Chaput JP; St-Pierre S; Tremblay A
    Mini Rev Med Chem; 2007 Jan; 7(1):3-10. PubMed ID: 17266632
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Obesity and cardiovascular physiology: impact of some pharmacological agents.
    Chaput JP; Bérubé-Parent S; Tremblay A
    Curr Vasc Pharmacol; 2005 Apr; 3(2):185-93. PubMed ID: 15853638
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis.
    Johansson K; Sundström J; Neovius K; Rössner S; Neovius M
    Obes Rev; 2010 Nov; 11(11):777-91. PubMed ID: 20025693
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines.
    Valsamakis G; McTernan PG; Chetty R; Al Daghri N; Field A; Hanif W; Barnett AH; Kumar S
    Metabolism; 2004 Apr; 53(4):430-4. PubMed ID: 15045687
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Managing obesity like any other chronic condition. Long-term therapy may reduce comorbidity as well.
    Agrawal M; Worzniak M; Diamond L
    Postgrad Med; 2000 Jul; 108(1):75-6, 79-82. PubMed ID: 10914120
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prevention and management of obesity: pharmacology .
    Finer N
    Proc Nutr Soc; 2000 Aug; 59(3):413. PubMed ID: 10997657
    [No Abstract]   [Full Text] [Related]  

  • 51. [Pharmacotherapy of obesity].
    Tripp B; Ludvik B
    Wien Med Wochenschr; 2004 Jul; 154(13-14):320-8. PubMed ID: 15368953
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis.
    Viner RM; Hsia Y; Tomsic T; Wong IC
    Obes Rev; 2010 Aug; 11(8):593-602. PubMed ID: 19922432
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacological intervention: the antiobesity approach.
    Rissanen A
    Eur J Clin Invest; 1998 Sep; 28 Suppl 2():27-30. PubMed ID: 9777325
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant.
    Rubio MA; Gargallo M; Isabel Millán A; Moreno B
    Public Health Nutr; 2007 Oct; 10(10A):1200-5. PubMed ID: 17903331
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Head-to-head studies evaluating efficacy of pharmaco-therapy for obesity: a systematic review and meta-analysis.
    Neovius M; Johansson K; Rössner S
    Obes Rev; 2008 Sep; 9(5):420-7. PubMed ID: 18208467
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drug treatments for obesity: orlistat, sibutramine, and rimonabant.
    Padwal RS; Majumdar SR
    Lancet; 2007 Jan; 369(9555):71-7. PubMed ID: 17208644
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Orlistat for obesity.
    Med Lett Drugs Ther; 1999 Jun; 41(1055):55-6. PubMed ID: 10436767
    [No Abstract]   [Full Text] [Related]  

  • 58. Pharmacological therapy of obesity: past, present, and future.
    Weigle DS
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2462-9. PubMed ID: 12788841
    [No Abstract]   [Full Text] [Related]  

  • 59. Modern medical management of obesity: the role of pharmaceutical intervention.
    Aronne LJ
    J Am Diet Assoc; 1998 Oct; 98(10 Suppl 2):S23-6. PubMed ID: 9787732
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Current and novel approaches to the drug therapy of obesity.
    Chaput JP; Tremblay A
    Eur J Clin Pharmacol; 2006 Oct; 62(10):793-803. PubMed ID: 16937118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.